Inactive Instrument

Chinook Therapeutics, Inc.

Equities

KDNY

US16961L1061

Biotechnology & Medical Research

Bob Azelby Joins Board of Chinook Therapeutics, Inc

April 17, 2023 at 07:43 am EDT

Chinook Therapeutics Inc. named former Eliem Therapeutics CEO Bob Azelby to its board of directors. Azelby had been Eliem's CEO since October 2020, according to his LinkedIn page, before which he was president and CEO of Alder BioPharmaceuticals, which was acquired by H. Lundbeck for $2.3 billion in 2019. Before Alder, he was chief commercial officer at Juno Therapeutics, which sold to Celgene for $9 billion in 2018.

Latest news about Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc. Announces Board Cessations	23-08-11	CI
Novartis Says it Completed Chinook Therapeutics Acquisition	23-08-11	MT
Novartis Completes Acquisition of Chinook Therapeutics for Up to $3.5 Billion	23-08-11	MT
Chinook Therapeutics, Inc.(NasdaqGM:KDNY) dropped from NASDAQ Composite Index	23-08-11	CI
Novartis AG completed the acquisition of Chinook Therapeutics, Inc. from a group of shareholders.	23-08-10	CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P Global BMI Index	23-08-10	CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index	23-08-10	CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P Biotechnology Select Industry Index	23-08-10	CI
North American Morning Briefing : Traders Absorb -2-	23-08-09	DJ
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index	23-08-09	CI
Wedbush Downgrades Chinook Therapeutics to Neutral From Outperform as Sale to Novartis Draws Closer; Keeps $42 Price Target	23-08-08	MT
Chinook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
North American Morning Briefing : Stock Futures -2-	23-08-02	DJ
Wells Fargo Downgrades Chinook Therapeutics to Equalweight From Overweight, Adjusts Price Target to $40 From $30	23-08-01	MT
ANALYST RECOMMENDATIONS : Meta, Thermo Fisher, Union Pacific, Domino's Pizza...	23-08-01
Chinook Therapeutics Says First Patient Enrolled in Phase 3 Trial of Zigakibart to Treat IgA Nephropathy	23-07-28	MT
Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy	23-07-28	CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) added to Russell 3000E Growth Index	23-06-23	CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell 3000E Index	23-06-23	CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell Microcap Index	23-06-23	CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell Microcap Value Index	23-06-23	CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell 3000E Value Index	23-06-23	CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) added to Russell 3000 Growth Index	23-06-23	CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) added to Russell 2500 Growth Index	23-06-23	CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) added to Russell Small Cap Comp Growth Index	23-06-23	CI

Chart Chinook Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
ARGENX SE	+2.71%	22.33B
BIONTECH SE	-12.77%	22.19B
GENMAB A/S	-7.05%	18.69B
WUXI APPTEC CO., LTD.	-38.36%	17.74B
BEIGENE, LTD.	-6.50%	17.64B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	14.05B
SAREPTA THERAPEUTICS, INC.	+37.20%	12.51B

Bio Therapeutic Drugs